No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis (MG). Most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Severe cases and acute worsening require intravenous immunoglobulin or plasmapheresis ...
Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995; 37(Suppl. 1): S2–S13 Article PubMed Google Scholar Lewis RA, Selwa JF, Lisak RP Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol 1995; 37(Suppl...
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antib...
Myasthenia gravis is a neuromuscular disease that presents clinically as fluctuating weakness of one or more skeletal muscle groups. Weakness becomes more severe with exercise and improves with rest. The disease is caused by an autoimmune reaction at or near the post-synaptic nicotinic acetylcholine re...
Becausepatients with seronegative myasthenia gravis (SNMG)respond to immunotherapy and have very similar clinicaland pathological features to seropositive disease, it issuspected that this condition is also mediated byantibodies. Recent studies su...
The application of immunotherapy, such as corticosteroids, immunosuppressants, and thymectomy,have increased compared with the use of cholinesterase inhibitors duringthe last 20 years. 展开 关键词: myasthenia gravis acetylcholine receptor muscle-specific tyrosine kinase late onset myasthenia gravis ...
Drugs to suppress your immune system.Most people with myasthenia gravis need medication that slows down the immune system. At first, you may get strong steroids like prednisone. After your symptoms improve, your doctor may transition you to nonsteroidal immunotherapy. ...
Myasthenia Gravis and Myasthenia-Like Syndromes are associated with patients treated with anti-PD-1/PD-L1 agents likenivolumabandpembrolizumab. It has also been reported with anti-CTLA-4 agents likeipilimumab. Patients withmyastheniagravis and myasthenia-like syndromes usually present with symptoms such ...
Myasthenia gravis (MG) is undoubtedly the most thoroughly understood neuromuscular autoimmune disease, and is perhaps the best understood of all human autoimmune disorders. The clinical features of muscle weakness and fatigue were first recognized in the seventeenth century1, and were well described by...
Myasthenia gravis is a neuromuscular disorder characterized by muscle weakness and fatigue, particularly in muscles controlled by the bulbar nuclei. It is believed to be an autoimmune response and is more common in women. AI generated definition based on: Sedation (Fifth Edition), 2010 ...